Global Pharmaceutical Continuous Manufacturing Market 2023-2029

February 2023 | 90 pages | ID: GFE079B9C034EN
Gen Consulting Company

Abstracts

For decades, pharmaceutical firms have manufactured their products in batches. To streamline production, manufacturers have begun to apply continuous manufacturing technologies to the pharmaceutical production process. Continuous manufacturing is a method for manufacturing pharmaceutical products from end-to-end on a single, uninterrupted production line. This continuous production eliminates built-in production gaps and can shorten manufacturing times from months to days. Where batch manufacturing requires transporting, testing, and re-feeding materials from one process to the next, continuous processes execute all testing, feeding, and processing inline. The global pharmaceutical continuous manufacturing market was estimated at USD 1,778 million in 2022 and is expected to hit USD 5,241 million by 2029, registering a CAGR of 16.7% from 2023 to 2029 as per the latest market estimates.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global pharmaceutical continuous manufacturing market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, drug type, source, and region. The global market for pharmaceutical continuous manufacturing can be segmented by product: active pharmaceutical ingredients (APIs), finished dosage form (FDF). According to the research, the APIs segment had the largest share in the global pharmaceutical continuous manufacturing market. Pharmaceutical continuous manufacturing market is further segmented by drug type: large molecules, small molecules. In 2022, the small molecules segment made up the largest share of revenue generated by the pharmaceutical continuous manufacturing market. Based on source, the pharmaceutical continuous manufacturing market is segmented into: in-house, outsourced. Among these, the in-house segment was accounted for the highest revenue generator in 2022. On the basis of region, the pharmaceutical continuous manufacturing market also can be divided into: Asia Pacific, Europe, North America, Rest of the World (RoW).

Market Segmentation

By product: active pharmaceutical ingredients (APIs), finished dosage form (FDF)

By drug type: large molecules, small molecules

By source: in-house, outsourced

By region: Asia Pacific, Europe, North America, Rest of the World (RoW)

The report also provides analysis of the key companies of the industry and their detailed company profiles including Abbott Laboratories, Ajinomoto Althea, Inc., Almac Group, Applikon Biotechnology B.V. (Getinge AB), Cipla Limited, Continuus Pharmaceuticals, Inc., Corden Pharma GmbH (International Chemical Investors S.E.), Eli Lilly and Company, Eppendorf SE, FUJIFILM Holdings Corporation, GEA Group AG, Glatt GmbH, GSK plc, Hovione Limited, Johnson & Johnson, L.B. Bohle Maschinen und Verfahren GmbH, Lonza Group AG, Merck KGaA, Novartis AG, Pall Corporation, Pfizer Inc., Recipharm AB, SEQENS SAS, Shanghai Pharmaceuticals Holding Co., Ltd., Shionogi & Company, Limited, SK biotek Ireland Limited, Syntegon Technology GmbH, Thermo Fisher Scientific Inc., Vertex Pharmaceuticals Incorporated, WuXi Biologics Co., Ltd., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report

• To analyze and forecast the market size of the global pharmaceutical continuous manufacturing market.
• To classify and forecast the global pharmaceutical continuous manufacturing market based on product, drug type, source, region.
• To identify drivers and challenges for the global pharmaceutical continuous manufacturing market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global pharmaceutical continuous manufacturing market.
• To identify and analyze the profile of leading players operating in the global pharmaceutical continuous manufacturing market.

Why Choose This Report

• Gain a reliable outlook of the global pharmaceutical continuous manufacturing market forecasts from 2023 to 2029 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY PRODUCT

Active pharmaceutical ingredients (APIs)
Finished dosage form (FDF)

PART 6. MARKET BREAKDOWN BY DRUG TYPE

Large molecules
Small molecules

PART 7. MARKET BREAKDOWN BY SOURCE

In-house
Outsourced

PART 8. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
North America
Rest of the World (RoW)

PART 9. KEY COMPANIES

Abbott Laboratories
Ajinomoto Althea, Inc.
Almac Group
Applikon Biotechnology B.V. (Getinge AB)
Cipla Limited
Continuus Pharmaceuticals, Inc.
Corden Pharma GmbH (International Chemical Investors S.E.)
Eli Lilly and Company
Eppendorf SE
FUJIFILM Holdings Corporation
GEA Group AG
Glatt GmbH
GSK plc
Hovione Limited
Johnson & Johnson
L.B. Bohle Maschinen und Verfahren GmbH
Lonza Group AG
Merck KGaA
Novartis AG
Pall Corporation
Pfizer Inc.
Recipharm AB
SEQENS SAS
Shanghai Pharmaceuticals Holding Co., Ltd.
Shionogi & Company, Limited
SK biotek Ireland Limited
Syntegon Technology GmbH
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Incorporated
WuXi Biologics Co., Ltd.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER